Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?

Authors
  • Herbild, Louise
  • Bech, Mickael
  • Gyrd-Hansen, Dorte
  • Christensen, Mona
  • Werge, Thomas
  • Nielsen, Kirsten Annette
Type
Published Article
Journal
Scandinavian journal of public health
Publication Date
Mar 01, 2011
Volume
39
Issue
2
Pages
147–155
Identifiers
DOI: 10.1177/1403494810393300
PMID: 21257648
Source
Medline
License
Unknown

Abstract

Based on this natural experiment we were not able to document statistically significant differences in total costs between treatment sites that had guidelines recommending pharmacogenetic testing, relative to sites without such guidelines, over a period of one year. However, guidelines of pharmacogenetic testing and possibly also therapeutic drug monitoring seem to lead to reductions in costs for primary care services. In the case of the former, reductions do, however, seem to be outweighed by increases in costs for psychiatric and non-psychiatric inpatient stays. In conclusion, no statistically significant differences in total direct costs across sites with different treatment strategies were found.

Report this publication

Statistics

Seen <100 times